Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Johnson and Johnson
Dow
Boehringer Ingelheim

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Alpharma Us Pharms Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for ALPHARMA US PHARMS, and what generic and branded alternatives to ALPHARMA US PHARMS drugs are available?

ALPHARMA US PHARMS has sixty-one approved drugs.



Summary for Alpharma Us Pharms
US Patents:0
Tradenames:43
Ingredients:40
NDAs:61

Drugs and US Patents for Alpharma Us Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alpharma Us Pharms FLUOCINOLONE ACETONIDE fluocinolone acetonide CREAM;TOPICAL 088361-001 Jan 16, 1984 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate SUSPENSION;ORAL 062200-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate SUSPENSION;ORAL 062200-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms DIPHENHYDRAMINE HYDROCHLORIDE diphenhydramine hydrochloride SYRUP;ORAL 070497-001 Apr 25, 1989 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms FLUOCET fluocinolone acetonide CREAM;TOPICAL 088360-001 Jan 16, 1984 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms TRIPLE SULFA trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) SUSPENSION;ORAL 080280-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms NYSTATIN nystatin SUSPENSION;ORAL 062571-001 Oct 29, 1985 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Alpharma Us Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-002 Approved Prior to Jan 1, 1982 4,620,974   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-006 Approved Prior to Jan 1, 1982 4,620,974   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-004 Approved Prior to Jan 1, 1982 4,620,974   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
McKinsey
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.